← Markets

Cogent Biosciences, Inc.

COGT · NASDAQ

Market closed$39.08$1.14 (+3.00%)After hours $38.89 · -0.49%

Key statistics

Previous close$37.94
Open$37.34
Day high$39.39
Day low$37.07
52-week high$43.73
52-week low$10.38
Market cap6.68B
Volume1.91M
Average volume2.40M
P/E ratio-18.52
Forward P/E—
EPS-2.11
Dividend yield0.00%

Market context

Why it moved

COGT shares rose amid a broadly positive market sentiment, likely driven by sector-specific momentum and investor optimism in the biotech and royalty pharma space as markets responded to easing inflation expectations and favorable macro conditions.

SubstackYahoo FinanceWallstreetcourierWccm Eccomas2026Axisdirect

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Cogent Biosciences rose roughly 2% as investor attention remained focused on the company's New Drug Application for bezuclastinib, filed with the FDA on June 30 for the treatment of Advanced Systemic Mastocytosis and backed by data from the APEX key trial. CEO Andrew Robbins has expressed confidence in securing initial approvals by year-end 2026, with the company also advancing a JAK2 V617F mutation-specific inhibitor toward an IND filing. The gain came against a supportive biotech backdrop, with UBS upgrading healthcare as a key allocation focus amid improving fundamentals and M&A tailwinds.

2.0514

July 14, 2026Cogent Biosciences gained nearly 3% in regular trading and continued rising in after-hours, outperforming the healthcare sector (XLV essentially flat) amid a broader market rebound following cooler-than-expected June CPI data. The rally builds on strong investor conviction in lead asset bezuclastinib, with multiple NDAs submitted across Non-Advanced and Advanced Systemic Mastocytosis and GIST, a planned U.S. commercial launch in H2 2026, and a $900M+ cash runway through 2028. Analysts hold a consensus Buy with a median price target of $50, implying meaningful upside from current levels.

2.803

July 14, 2026Cogent Biosciences shares fell sharply, declining alongside broader market weakness driven by renewed U.S.-Iran military tensions that sent oil prices surging and rattled equity sentiment. The pullback comes despite a strong fundamental backdrop: Cogent recently submitted an NDA for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) following compelling APEX trial data, and the company is tracking toward a potential commercial launch in the second half of 2026. With a consensus analyst Buy rating and median price target of $50, the near-term macro headwinds appear to be overshadowing the company's regulatory and clinical momentum.

-3.6275

July 11, 2026Cogent Biosciences fell roughly 4% after being removed from several Russell indexes, adding technical selling pressure even as the company's FDA narrative remains constructive. The decline came despite Cogent's recent NDA submission to the FDA for bezuclastinib in advanced systemic mastocytosis, backed by strong APEX trial data showing disease modification and undetectable KIT D816V levels in a subset of patients. Analysts maintain a predominantly bullish stance with a consensus target near $43.73, and broader biotech has been quietly outperforming as XLV hit record highs — making the Russell rebalancing-driven pullback a key overhang to watch ahead of upcoming PDUFA dates.

-4.0484

July 10, 2026Cogent Biosciences closed modestly higher, outperforming the broader healthcare sector (XLV essentially flat in after-hours) as investor focus remains squarely on the company's FDA New Drug Application for bezuclastinib in advanced systemic mastocytosis, backed by strong APEX trial data showing high overall response rates and meaningful disease modification including bone marrow normalization. The stock also benefits from a broadly bullish biotech backdrop, with Jim Cramer and analysts highlighting biotech as the market's hottest sector amid expectations of accelerating M&A — a tailwind for clinical-stage names with clean late-stage data like Cogent. Analysts carry a consensus price target of ~$43.73, implying modest additional upside, while a recent Russell index exclusion may add some near-term technical pressure.

1.351

July 3, 2026Cogent Biosciences edged higher, extending momentum from its June 30 NDA submission to the FDA for bezuclastinib in Advanced Systemic Mastocytosis—the third NDA filing in six months—backed by strong APEX trial data showing 65% ORR. In after-hours, shares slipped ~1.9%. With 13 analysts maintaining a Buy consensus and an average price target of ~$54, the stock trades at a notable premium (P/B of 12.1x vs. industry average of 2.7x), prompting valuation debate even as key PEAK and SUMMIT FDA reviews remain on track for anticipated Q4 2026 approvals.

0.5457

July 1, 2026Cogent Biosciences closed essentially flat as two major developments competed for investor attention: the company submitted its third FDA New Drug Application in six months for bezuclastinib in Advanced Systemic Mastocytosis, backed by an impressive 65–81% overall response rate from the APEX pivotal trial, with Q4 2026 approvals anticipated across all three submissions. However, shares surged nearly 3% in after-hours trading, as the NDA news overshadowed last week's broad Russell index removals—which had raised concerns about passive fund outflows and liquidity—with volume running well above average at more than double the daily norm.

-0.1033

June 30, 2026Cogent Biosciences gained nearly 2% on above-average volume, buoyed by a broader market rebound after the U.S. and Iran agreed to halt military strikes in the Strait of Hormuz. The stock's advance comes as investors remain focused on the company's advancing regulatory pipeline — the FDA has accepted two NDAs for bezuclastinib (in GIST and non-advanced systemic mastocytosis) with Priority Review — while Russell index rebalancing removed COGT from several benchmarks including the Russell Microcap and Russell 3000E Growth indexes. Analysts maintain a buy consensus with an average target of $54.25, implying ~40% upside from current levels.

1.6798

Stock Titan · July 6, 2026Cogent Biosciences (COGT) director takes options in lieu of cashSeeking Alpha · June 14, 2026Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT)Stock Titan · June 12, 2026Experimental drug cuts mast cell disease markers in most AdvSM patientsStock Titan · May 28, 2026Cancer drug combo halves disease progression risk in GIST trialInvesting News Network · May 28, 2026Cogent Biosciences Announces FDA Acceptance of New Drug Application with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GISTStock Titan · May 27, 2026Six new Cogent Biosciences hires get stock options and RSUsInvesting News Network · May 5, 2026Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial ResultsGlobeNewswire · April 1, 2026Cogent Biosciences Announces Submission of New Drug

Peers

S&P 500SPX · $7,457.69-1.01%Roivant Sciences Ltd.ROIV · $34.51+1.71%BioNTech SEBNTX · $90.94-0.68%Insmed IncorporatedINSM · $108.00+0.50%Viatris Inc.VTRS · $17.43+0.58%Genmab A/SGMAB · $28.72-0.90%Novartis AGNVS · $153.48+0.49%Arcutis Biotherapeutics, Inc.ARQT · $27.98+0.87%ARS Pharmaceuticals, Inc.SPRY · $7.10-4.86%Vericel CorporationVCEL · $47.00-1.69%BioCryst Pharmaceuticals, Inc.BCRX · $9.40+3.24%Immunocore Holdings plcIMCR · $34.81+0.99%